References Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy MHC class I gene expression and regulation Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer  Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer Clinical significance of tumor-infiltrating lymphocytes in breast cancer Immunotherapy treatment for triple negative breast cancer Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma Activation of ERalpha signaling differentially modulates IFN-gamma induced HLA-class II expression in breast cancer cells Directing traffic: how to effectively drive T cells into tumors Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome